Cargando…

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophag...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauvin, Jade, Frégeau, Geneviève, Elimam, Hanan, Ménard, Liliane, Huynh, David, Lê, Catherine, Ahsanullah, Ahsanullah, Lubell, William D., Ong, Huy, Marleau, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270736/
https://www.ncbi.nlm.nih.gov/pubmed/37332345
http://dx.doi.org/10.3389/fphar.2023.1204905
_version_ 1785059377932140544
author Gauvin, Jade
Frégeau, Geneviève
Elimam, Hanan
Ménard, Liliane
Huynh, David
Lê, Catherine
Ahsanullah, Ahsanullah
Lubell, William D.
Ong, Huy
Marleau, Sylvie
author_facet Gauvin, Jade
Frégeau, Geneviève
Elimam, Hanan
Ménard, Liliane
Huynh, David
Lê, Catherine
Ahsanullah, Ahsanullah
Lubell, William D.
Ong, Huy
Marleau, Sylvie
author_sort Gauvin, Jade
collection PubMed
description Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in atherosclerotic lesion progression and acts as an efferocytic molecule in the resolution of advanced plaque. In previous studies, linear azapeptide CD36 ligands were shown to exhibit anti-atherosclerotic properties. In the present study, a novel potent and selective macrocyclic azapeptide CD36 ligand, MPE-298, has proven effective in protecting against atherosclerosis progression. Features of greater plaque stability were observed after 8 weeks of daily injections with the cyclic azapeptide in apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet.
format Online
Article
Text
id pubmed-10270736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102707362023-06-16 A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice Gauvin, Jade Frégeau, Geneviève Elimam, Hanan Ménard, Liliane Huynh, David Lê, Catherine Ahsanullah, Ahsanullah Lubell, William D. Ong, Huy Marleau, Sylvie Front Pharmacol Pharmacology Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in atherosclerotic lesion progression and acts as an efferocytic molecule in the resolution of advanced plaque. In previous studies, linear azapeptide CD36 ligands were shown to exhibit anti-atherosclerotic properties. In the present study, a novel potent and selective macrocyclic azapeptide CD36 ligand, MPE-298, has proven effective in protecting against atherosclerosis progression. Features of greater plaque stability were observed after 8 weeks of daily injections with the cyclic azapeptide in apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10270736/ /pubmed/37332345 http://dx.doi.org/10.3389/fphar.2023.1204905 Text en Copyright © 2023 Gauvin, Frégeau, Elimam, Ménard, Huynh, Lê, Ahsanullah, Lubell, Ong and Marleau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Gauvin, Jade
Frégeau, Geneviève
Elimam, Hanan
Ménard, Liliane
Huynh, David
Lê, Catherine
Ahsanullah, Ahsanullah
Lubell, William D.
Ong, Huy
Marleau, Sylvie
A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title_full A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title_fullStr A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title_full_unstemmed A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title_short A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
title_sort cyclic azapeptide ligand of the scavenger receptor cd36/sr-b2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein e-deficient mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270736/
https://www.ncbi.nlm.nih.gov/pubmed/37332345
http://dx.doi.org/10.3389/fphar.2023.1204905
work_keys_str_mv AT gauvinjade acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT fregeaugenevieve acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT elimamhanan acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT menardliliane acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT huynhdavid acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT lecatherine acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT ahsanullahahsanullah acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT lubellwilliamd acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT onghuy acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT marleausylvie acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT gauvinjade cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT fregeaugenevieve cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT elimamhanan cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT menardliliane cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT huynhdavid cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT lecatherine cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT ahsanullahahsanullah cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT lubellwilliamd cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT onghuy cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice
AT marleausylvie cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice